I Said No to Their Drug Trials for Cancer and I’m Still Here

RxLeaf July 1, 2018 0 comments

Ron is a five-time cancer surviver and he credits cannabis. 

Editor’s Note: Any testimonials or endorsements found on this site are for anecdotal purposes only. The information in Rxleaf testimonials is not intended as direct medical advice, nor should it be relied upon as a substitute for consultations with qualified healthcare professionals who are intimately knowledgeable about your individual medical needs.

My name is Ron and I am a 20 year (5 time) Non Hodgkins Lymphoma survivor. I recently became disabled by reduced heart function. Half of it is dead from chemotherapy drugs taken 10 years ago.

Essentially, I was told by my oncologist 26 months ago, I would be dead in 2yrs. In fact, he said it would metastasize this time because that’s what studies show. Studies didn’t show what THC & CBD oil infusion can do. I cleared that up in my own experiment.

When I first asked about it, my oncologist said, “Oh, you like to get high?” So he’s not my oncologist anymore! He wanted me to do maintenance drugs for 2 years. Then he wanted to put me in a drug trial. He insisted that I needed it. I would be dead now if I fed his wallet instead of my health.

I quit all the opiates and nerve blockers and Xanax with cannabis.

From RxLeaf: Where are things with Cannabis Drug Trials for Cancer?

In a review of the current and completed studies published on ClinicalTrials.gov, there are already dozens looking at cannabis for cancer. Yet, most (if not all) of these studies explore the benefits of the plant for palliative care, cancer-related pain, or to reduce the adverse effects of chemotherapy and radiation.

Few have ever looked at the potential of cannabis to target cancer itself, at least in later stages of clinical research.

A single study, published in 2006 1)Guzmán, M., Duarte, M. J., Blázquez, C., Ravina, J., Rosa, M. C., Galve-Roperh, I., Sánchez, C., Velasco, G., & González-Feria, L. (2006). A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British journal of cancer, 95(2), 197–203. https://doi.org/10.1038/sj.bjc.6603236) tested THC’s anticancer potential among nine cancer patients. As per the results, patients tolerated THC well with few side effects. Most importantly, THC appears to have slowed tumor cell proliferation and reduced tumor-cell Ki67 immunostaining in two patients. Unfortunately, there hasn’t been much progress within cannabis drug trials for cancer since 2006.

The slow pace of research on cannabis’ antitumor potential likely comes down to the federal scheduling of the plant. Cannabis remains strictly controlled, making it near-impossible to study the plant using federal funds in the US.

Preliminary Studies of Cannabis for Cancer

Patients are still waiting on cannabis-based drug trials for cancer, but that hasn’t stopped many from diving into cannabinoids for their own treatments. Further, just like Ron’s story, there are hundreds (if not thousands) of anecdotal stories online of people describing positive results from plant-based medicine.

Both in-vivo and in-vitro studies on cannabinoids for cancer are strongly suggestive that it could reduce the spread of cancer cells and promote cancer cell apoptosis. These are early phase but promising.

Likewise, in the 2016 ((Velasco, G., Sánchez, C., & Guzmán, M. (2016). Anticancer mechanisms of cannabinoids. Current oncology (Toronto, Ont.), 23(2), S23–S32. https://doi.org/10.3747/co.23.3080summary, “Anticancer mechanisms of cannabinoids,” the authors conclude there is at least enough evidence for proof of concept behind cannabis for cancer. According to their review, cannabinoids seem to improve the efficacy of other cancer therapies, promote cancer cell apoptosis, and in some cases, inhibit metastasis. [2]

Preliminary support in scientific literature is the first critical step towards well-controlled clinical trials. Following the growing demand among the American public and a majority of states with legal access, it’s only a matter of time before the American government opens up funding to better medical cannabis research.

References   [ + ]

1.Guzmán, M., Duarte, M. J., Blázquez, C., Ravina, J., Rosa, M. C., Galve-Roperh, I., Sánchez, C., Velasco, G., & González-Feria, L. (2006). A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British journal of cancer, 95(2), 197–203. https://doi.org/10.1038/sj.bjc.6603236) tested THC’s anticancer potential among nine cancer patients. As per the results, patients tolerated THC well with few side effects. Most importantly, THC appears to have slowed tumor cell proliferation and reduced tumor-cell Ki67 immunostaining in two patients. Unfortunately, there hasn’t been much progress within cannabis drug trials for cancer since 2006.

The slow pace of research on cannabis’ antitumor potential likely comes down to the federal scheduling of the plant. Cannabis remains strictly controlled, making it near-impossible to study the plant using federal funds in the US.

Preliminary Studies of Cannabis for Cancer

Patients are still waiting on cannabis-based drug trials for cancer, but that hasn’t stopped many from diving into cannabinoids for their own treatments. Further, just like Ron’s story, there are hundreds (if not thousands) of anecdotal stories online of people describing positive results from plant-based medicine.

Both in-vivo and in-vitro studies on cannabinoids for cancer are strongly suggestive that it could reduce the spread of cancer cells and promote cancer cell apoptosis. These are early phase but promising.

Likewise, in the 2016 ((Velasco, G., Sánchez, C., & Guzmán, M. (2016). Anticancer mechanisms of cannabinoids. Current oncology (Toronto, Ont.), 23(2), S23–S32. https://doi.org/10.3747/co.23.3080

Post a comment

Your email address will not be published. Required fields are marked *

Click to Hide Advanced Floating Content

FREE SHIPPING OVER $50